Abstract
Epigallocatechin gallate (EGCG), irreversibly inhibits cytochrome P450 (CYP) 3A subfamily and P-glycoprotein (P-gp) in vitro. This study investigated the effect of oral EGCG on the pharmacokinetics of intravenous and oral nicardipine in rats. Nicardipine was administered orally (12 mg/kg) or intravenously (4 mg/kg) with or without oral EGCG (0.5, 3 or 10 mg/kg) to rats. Compared to controls (without EGCG), the total areas under the plasma concentration-time curve (AUCs) of intravenous nicardipine were greater with oral EGCG. Compared to controls (without EGCG), the AUCs of oral nicardipine and the extent of absolute oral bioavailability (F) were also greater with oral EGCG. The above data suggest that oral EGCG inhibited both the hepatic CYP3A subfamily and intestinal P-gp.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chiou, W. L., Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm., 6, 539–549 (1978).
Chu, D. C. and Juneja, L. R., Chemistry and Applications of Green Tea, in: Yamamoto, T., Juneja, L. R., Chu, D. C., Kim, M. (Eds.). CRC Press, New York, pp. 13–22, (1997).
Dixon, R. A. and Steele, C. L., Flavonoids and isoflavonoidsa gold mine for metabolic engineering. Trends Plant Sci., 4, 394–400 (1999).
Eastwood, R. J., Galustian, C., Bhamra, R. K., and Holt, D. W., High-performance liquid chromatographic method for the measurement of nicardipine in plasma or serum. J. Chromatogr., 530, 463–468 (1990).
Gibaldi, M. and Perrier, D., Pharmacokinetics (2nd edn). Marcel-Dekker, New York (1982).
Graham, D. J., Dow, R. J., Freedman, D., Mroszczak, E., and Ling, T., Pharmacokinetics of nicardipine following oral and intravenous administration in man. Postgrad. Med. J., 4, 7–10 (1984).
Graham, D. J., Dow, R. J., Hall, D. J., Alexander, O. F., Mroszczak, E. J., and Freedman, D., The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br. J. Clin. Pharmacol., 1, 23–28 (1985).
Guengerich, F. P., Martin, M. V., Beaune, P. H., Kre-mers, P., Wolff, T., and Waxman, D. J., Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261, 5051–5060 (1986).
Hasegawa, G. R., Nicardipine, nitrendipine, and bepridil: new calcium antagonists for cardiovascular disorders. Clin. Pharm., 7, 97–108 (1988).
Higdon, J. V. and Frei, B., Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr., 43, 89–143 (2003).
Hong, J., Lambert, J. D., Lee, S. H., Sinko, P. J., and Yang, C. S., Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem. Biophys. Res. Commun., 310, 222–227 (2003).
Hu, Y. P., Chapey, C., and Robert, J., Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Lett., 109,203–209 (1996).
Hysing, E. S., Chelly, J. E., Doursout, M. F., Hartley, C., and Merin, R. G., Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. III. Nicardipine and isoflurane. Anaesthesiology, 65, 385–391 (1986).
Jodoin, J., Demeule, M., and Beliveau, R., Inhibition of the mutldrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta, 1542, 149–159 (2002).
Kishi, Y., Okumura, F., and Furuya, H., Haemodynamic effects of nicardipine hydrochloride. Studies during its use to control acute hypertension in anaesthetized patients. Br. J. Anaesth., 56, 1003–1007 (1984).
Kitagawa, S., Nabekura, T., and Kamiyama, S., Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol., 56, 1001–1005 (2004).
Kuroda, Y. and Hara, Y., Antimutagenic and anticarcinogenic activity of tea polyphenols. Mutat. Res., 436, 69–97 (1999).
Muto, S., Fujita, K., Yamazaki, Y., and Kamataki, T., Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat. Res., 479, 197–206 (2001).
Nijveldt, R. J., van Nood, E., van Hoorn, D. E., Boelens, P. G., Van Norren, K., and Van Leeuwen, P. A., Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr., 74, 418–425 (2001).
Qian, F., Wei, D., Zhang, Q., and Yang, S., Modulation of Pglycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Biomed. Pharmacother., 59, 64–69 (2005).
Wang, E. J., Casciano, C. N., Clement, R. P., and Johnson, W. W., Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim. Biophys. Acta, 1481, 63–74 (2000).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, JS., Burm, JP. Effects of oral epigallocatechin gallate on the pharmacokinetics of nicardipine in rats. Arch. Pharm. Res. 32, 1721–1725 (2009). https://doi.org/10.1007/s12272-009-2209-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-009-2209-7